March 31, 2011 | by Cytos Biotechnology Ltd
|
Reading time: 2 minutes
March 31, 2011, Cytos Biotechnology Ltd (SIX:CYTN) announced today that it has entered a Cooperative Research and Development Agreement (CRADA) for the preclinical development of a malaria vaccine with the Walter Reed Army Institute of Research (WRAIR). Cytos Biotechnology will provide its virus-like particle (VLP) based vaccination technology and expertise whilst WRAIR will contribute a malaria antigen candidate. Vaccine candidates generated by Cytos Biotechnology will be tested in preclinical models of malaria disease by WRAIR.
Dr Martin Bachmann, CSO of Cytos Biotechnology commented “The WRAIR is the largest and most diverse biomedical research laboratory in the US Department of Defense and we keenly welcome the opportunity to work with them in malaria vaccine R&D. Malaria is a major disease burden for people living in at-risk areas and it poses a significant threat to military personnel serving in such regions and to travelers. Consequently, the development of new vaccines to prevent malaria is an important area of focus for vaccine R&D. This collaboration is our second malaria vaccine partnership with leading research institutes in the United States of America following the recent announcement of our collaboration with the NIH and SAIC. This new collaboration demonstrates the continuing attractiveness of the VLP-platform for partnering in the eyes of leading biomedical organizations in academia, government agencies, and industry.”
Contact
Cytos Biotechnology Ltd Wolfgang A. Renner, PhD Chief Executive Officer Cytos Biotechnology Ltd Phone: +41 44 733 47 03 Fax: +41 44 733 47 04 e-Mail: wolfgang.renner@cytos.com Website: www.cytos.com
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « United States Army and Cytos Biotechnology Collaborate on Malaria Vaccines Research »
Source: Cytos Biotechnology Ltd, Press release